Kedaara Capital commits $240M to AI life sciences firm Axtria
Transaction combines secondary share sales and a company buyback, giving staff and early investors a cash exit while signalling private equity confidence in the life sciences AI firm.
Private equity firm Kedaara Capital has completed a $240 million transaction that supplies liquidity to employees and early investors in Axtria, an agentic artificial intelligence (AI) and data analytics firm that serves the global life sciences sector.
The deal is structured as a combination of a secondary sale of existing shares and a company-sponsored share buyback, rather than a straightforward primary capital injection into Axtria’s balance sheet. This means the money mainly provides exits for long-standing staff and early backers.
“At Axtria, we are… building a company… that values its people and their contributions through long-term value creation. Offering liquidity to our current and former employees is a testament to that ethos,” said Jaswinder Chadha, President and CEO, Axtria.
Founded in 2010, Axtria is an AI-first cloud software and analytics provider for life sciences clients. The company says it supports 18 of the top 20 global pharmaceutical firms and more than 100 organisations across 75 countries.
Its platform portfolio includes a new agentic offering called Axtria InsightsMAx.ai and other products such as SalesIQ, CustomerIQ, MarketingIQ, and DataMAx, which the firm says help move customers from experimentation to scaled AI deployment.
Agentic AI refers to systems that act with a degree of autonomy, planning and executing tasks rather than simply offering analysis or recommendations. In life sciences, it is being applied to speed up clinical research, sharpen commercial strategies and improve patient engagement by turning vast data into actionable insights.
The field is expanding quickly as companies move from pilot projects to large-scale use. Experts see agentic AI as one of the fastest-growing areas of enterprise technology, with pharmaceutical and biotech firms adopting it to cut development time and support better decisions. Axtria has positioned its InsightsMAx.ai platform in this space to help clients operationalise AI agents across their organisations.
“We are delighted to support Axtria’s talented workforce as they continue to scale as a trusted partner, helping life sciences companies harness the power of technology and Agentic AI,” noted Sunish Sharma, Founder and Managing Partner of Kedaara Capital.
Meanwhile, Aashwit Mahajan, Director and Co-Lead for Technology and Technology Services at Kedaara Capital, said the PE firm looked forward to supporting Axtria in both organic and inorganic growth while strengthening its differentiated value proposition.
The companies emphasised the employee-focused nature of the deal but did not disclose a valuation or the split between the secondary sale and the buyback.
With over $5 billion under management, Kedaara Capital has invested in market-leading businesses across sectors such as consumer, financial services, pharma/healthcare, and technology/business services. In January, the Mumbai-based PE firm invested $350 million in Impetus Technologies, a data, analytics, and AI solutions provider.